Prevention of group B streptococcal disease in the first 3 months of life: Would routine maternal immunization during pregnancy be cost-effective?

Vaccine

Volumn 32, Issue 37, 2014, Pages 4778-4785

  Oster, Gerry ^a   Edelsberg, John ^a   Hennegan, Kalin ^a   Lewin, Clement ^b   Narasimhan, Vas ^c   Slobod, Karen ^c   Edwards, Morven S ^d   Baker, Carol J ^d  

^a POLICY ANALYSIS INC PAI   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Novartis Vaccines Cambridge   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Group B streptococcus; Maternal immunization

Indexed keywords

STREPTOCOCCUS VACCINE; TRIPLE VACCINE;

ARTICLE; CHILD DEATH; COST CONTROL; COST EFFECTIVENESS ANALYSIS; GROUP B STREPTOCOCCAL INFECTION; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; MATERNAL WELFARE; PREGNANCY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEROTYPE; STREPTOCOCCUS AGALACTIAE; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; INFANT; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; STATISTICAL MODEL; STREPTOCOCCAL INFECTIONS; VACCINATION; VERTICAL TRANSMISSION;

COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MODELS, ECONOMIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; QUALITY-ADJUSTED LIFE YEARS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; UNITED STATES; VACCINATION;

EID: 84905228319     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.003     Document Type: Article

References (39)

1. Schrag S.J., Zell E.R., Lynfield R., Roome A., Arnold K.E., Craig A.S., et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002, 347:233-239.
2. Centers for Disease Control and Prevention Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Morb Mortal Wkly Rep 1996, 45:1-24.
3. Centers for Disease Control and Prevention Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. MMWR 2010, 59(RR-10):1-36.
4. Centers for Disease Control and Prevention Active Bacterial Core Surveillance Report, Emerging Infections Program Network group B streptococcus, 2011 2012, Available at: http://www.cdc.gov/abcs/reports-findings/survreports/gbs11.html [accessed 20.06.13].
5. Van Dyke M., Phares C., Lynfield R., Thomas A.R., Arnold K.E., Craig A.S., et al. Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med 2009, 360:2626-2636.
6. Baker C.J., Dennis L.K. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976, 204:753-756.
7. Lin F.Y., Philips J.B., Azimi P.H., Weisman L.E., Clark P., Rhoads G.G., et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 2001, 184:1022-1028.
8. Lin F.Y., Weisman L.E., Azimi P.H., Philips J.B., Clark P., Regan J., et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004, 190:928-934.
9. Jordan H.T., Farley M.M., Craig A., Mohle-Boetani J., Harrison L.H., Petit S., et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease. Pediatr Infect Dis J 2008, 27:1057-1064.
10. Centers for Disease Control and Prevention Resistance in GBS for Laboratory Personnel-Group B Strep 2010, Available at: http://www.cdc.gov/groupbstrep/lab/resistance.html [accessed 31.07.13].
11. U.S.Census Bureau Statistical abstract of the United States 2012.
12. Martin J.A., Hamilton B.E., Ventura S.J., Osterman M.J., Kirmeyer S., Matthews T.J., et al. Births: final data for 2009. Natl Vital Stat Rep 2011, 60(1):1-70.
13. Benitz W.E., Gould J.B., Druzin M.L. Risk factors for early-onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Pediatrics 1999, 103(6):e77.
14. Phares C.R., Lynfield R., Farley M.M., Mohle-Boetani J., Harrison L.H., Petit S., et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008, 299:2056-2065.
15. Schrag S.J., Zywicki S., Farley M.M., Reingold A.L., Harrison L.H., Lefkowitz L.H., et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000, 342:15-20.
16. Colbourn T., Asseburg C., Bojke L., Philips Z., Claxton K., Ades A.E., et al. Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses. Health Technol Assess 2007, 11:1-226. iii.
17. Murphy S.L., Xu J.Q., Kochanek K.D. Deaths preliminary data for 2010. National vital statistics reports; vol. 60, no. 4 2012, National Center for Health Statistics, Hyattsville, MD.
18. Garty B.Z., Ludomirsky A., Danon Y.L., Peter J.B., Douglas S.D. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1994, 1:667-669.
19. Simister N. Placental transport of immunoglobulin G. Vaccine 2003, 21:3365-3369.
20. Baker C.J., Rench M.A., Fernandez M., Paoletti L.C., Kasper D.L., Edwards M.S. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003, 188:66-73.
21. Healthcare Cost and Utilization Project. Available at: [accessed 8.07.13]. http://hcupnet.ahrq.gov/HCUPnet.app/HCUPnet.jsp.
22. Carroll A., Downs M. Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics 2006, 117:S287-S295.
23. Centers for Disease Control and Prevention Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment: United States, 2003. MMWR Morb Mortal Wkly Rep 2004, 53:57-59.
24. Shepard C.W., Ortega-Sanchez I.R., Scott R.D., Rosenstein N.E., ABCs Team Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005, 115:1220-1232.
25. Lieu T.A., Ray G.T., Black S.B., Butler J.C., Klein J.O., Breiman R.F., et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000, 283:1460-1468.
26. Ray G.T., Whitney C.G., Fireman B.H., Ciuryla V., Black S.B. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006, 25:494-501.
27. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359:821-832.
28. Gibbs R.S., Roberts D.J. Case 27-2007: a 30-year-old pregnant woman with intrauterine fetal death. N Engl J Med 2007, 357:918-925.
29. Davies H.D., Raj S., Adair C., Robinson J., McGeer A., Alberta GBS Study Group Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation. Pediatr Infect Dis J 2001, 20:879-884.
30. Terris-Prestholt F., Watson-Jones D., Mugeye K., Kumaranayake L., Ndeki L., Weiss H., et al. Is antenatal syphilis screening still cost effective in sub-Saharan Africa. Sex Transm Infect 2003, 79:375-381.
31. Schackman B.R., Neukermans C.P., Fontain S.N., Nolte C., Joseph P., Pape J.W., et al. Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in Haiti. PLoS Med 2007, 4:e183.
32. Mercer B. Antibiotics in the management of PROM and preterm labor. Obstet Gynecol Clin North Am 2012, 39:65-76.
33. Whidbey C., Harrell M.I., Burnside K., Ngo L., Becraft A.K., Iyer L.M., et al. A hemolytic pigment of Group B Streptococcus allows bacterial penetration of human placenta. J Exp Med 2013, 210:1265-1281.
34. Valkenburg-van den Berg A.W., Sprij A.J., Dekker F.W., Dörr P.J., Kanhai H.H. Association between colonization with group B streptococcus and preterm delivery: a systematic review. Acta Obstet Gynecol Scand 2009, 88:958-967.
35. Baker C., Carey V., Edwards M., Ewell M., Ferrieri P., Ferris D., et al. Women receiving group B Streptococcus serotype III tetanus toxoid (GBS III-TT) vaccine have reduced vaginal and rectal acquisition of GBS type III. Abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America October 2009, Abstract 186.
36. Centers for Disease Control and Prevention Seasonal influenza vaccination coverage among women who delivered a live-born infant - 21 states and New York City, 2009-10 and 2010-11 influenza seasons. MMWR Morb Mortal Wkly Rep 2013, 62:1001-1004.
37. Baker C.J., Rench M.A., McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003, 21:3468-3472.
38. Baker C.J., Carey V.J., Rench M.A., Edwards M.S., Hillier S.L., Kasper D.L., et al. Maternal antibody at delivery protects neonates from early-onset group B streptococcal disease. J Infect Dis 2014, 209:781-788.
39. Edmond K.M., Kortsalioudaki C., Scott S., Schrag S.J., Zaidi A.K., Cousens S., et al. Group B streptococcal disease in infants aged younger than 3 months: systemic review and meta-analysis. Lancet 2012, 379:547-556.